K Rowland‐Yeo

2.0k total citations · 1 hit paper
22 papers, 1.6k citations indexed

About

K Rowland‐Yeo is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Oncology. According to data from OpenAlex, K Rowland‐Yeo has authored 22 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pharmacology, 8 papers in Pediatrics, Perinatology and Child Health and 6 papers in Oncology. Recurrent topics in K Rowland‐Yeo's work include Pharmacogenetics and Drug Metabolism (12 papers), Pharmacological Effects and Toxicity Studies (7 papers) and Drug Transport and Resistance Mechanisms (6 papers). K Rowland‐Yeo is often cited by papers focused on Pharmacogenetics and Drug Metabolism (12 papers), Pharmacological Effects and Toxicity Studies (7 papers) and Drug Transport and Resistance Mechanisms (6 papers). K Rowland‐Yeo collaborates with scholars based in United Kingdom, United States and Australia. K Rowland‐Yeo's co-authors include Amin Rostami‐Hodjegan, Geoffrey T. Tucker, Masoud Jamei, Zoe Barter, Trevor N. Johnson, Lisa M. Almond, Koen Boussery, Sibylle Neuhoff, Eleanor Howgate and Junhong Yang and has published in prestigious journals such as Clinical Pharmacology & Therapeutics, Clinical Pharmacokinetics and Drug Metabolism and Disposition.

In The Last Decade

K Rowland‐Yeo

22 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development

2013 442 citations K Rowland‐Yeo et al. CPT Pharmacometrics & Systems Pharmacology profile →

Peers

Countries citing papers authored by K Rowland‐Yeo

Since Specialization

Citations

This map shows the geographic impact of K Rowland‐Yeo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K Rowland‐Yeo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K Rowland‐Yeo more than expected).

Fields of papers citing papers by K Rowland‐Yeo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K Rowland‐Yeo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K Rowland‐Yeo. The network helps show where K Rowland‐Yeo may publish in the future.

Co-authorship network of co-authors of K Rowland‐Yeo

This figure shows the co-authorship network connecting the top 25 collaborators of K Rowland‐Yeo. A scholar is included among the top collaborators of K Rowland‐Yeo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K Rowland‐Yeo. K Rowland‐Yeo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The use of quantitative clinical pharmacology approaches to support moxidectin dosing recommendations in lactation 2024 ·PLoS neglected tropical diseases ·Nolan Wood, (unknown), Sally Kinrade, Mark Sullivan, Craig R. Rayner, David Wesche, Kashyap Patel, K Rowland‐Yeo	2
2	Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future 2021 ·Clinical Pharmacology & Therapeutics ·Craig R. Rayner, Patrick F. Smith, David R. Andes, (unknown), Hartmut Derendorf, Lena E. Friberg, Debra Hanna, (unknown), Edward Mills, Thomas M. Polasek, Jason A. Roberts, Virna Schuck, Mark Shelton, David Wesche, K Rowland‐Yeo	53
3	How Does In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach 2016 ·Drug Metabolism and Disposition ·Trevor N. Johnson, Masoud Jamei, K Rowland‐Yeo	44
4	Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model 2016 ·Drug Metabolism and Disposition ·Lisa M. Almond, Sophie Mukadam, I. Gardner, (unknown), Susan Wong, Oliver Hatley, Sun Tee Tay, K Rowland‐Yeo, Masoud Jamei, Amin Rostami‐Hodjegan, Jane R. Kenny	91
5	Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6 2016 ·CPT Pharmacometrics & Systems Pharmacology ·Alice Ke, Zoe Barter, K Rowland‐Yeo, Lisa M. Almond	44
6	Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug–drug interactions 2016 ·European Journal of Pharmaceutical Sciences ·Howard Burt, Sibylle Neuhoff, Lisa M. Almond, Lu Gaohua, Matthew D. Harwood, Masoud Jamei, Amin Rostami‐Hodjegan, Geoffrey T. Tucker, K Rowland‐Yeo	97
7	CPT: Pharmacometrics & Systems Pharmacology 2013 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), (unknown), K Rowland‐Yeo, Masoud Jamei, Anders Åsberg, Hege Christensen, (unknown), Amin Rostami‐Hodjegan	1
8	Evaluation of anIn SilicoPBPK Post‐Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine 2013 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), (unknown), K Rowland‐Yeo, Masoud Jamei, Anders Åsberg, Hege Christensen, Darren M. Ashcroft, Amin Rostami‐Hodjegan	25
9	Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans 2013 ·Xenobiotica ·Christopher R. Gibson, Ping Lü, (unknown), (unknown), Zoe Barter, K Rowland‐Yeo, Mark Stroh, Eseng Lai, Deborah A. Nicoll‐Griffith	15
10	Differences in Cytochrome P450-Mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically Based Pharmacokinetic Modelling 2013 ·Clinical Pharmacokinetics ·Zoe Barter, Geoffrey T. Tucker, K Rowland‐Yeo	101
11	A Mechanistic Framework for In Vitro–In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drug–Drug Interaction Between Rosuvastatin and Cyclosporine 2013 ·Clinical Pharmacokinetics ·Masoud Jamei, (unknown), Sibylle Neuhoff, Zoe Barter, Junhong Yang, Amin Rostami‐Hodjegan, K Rowland‐Yeo	138
12	Evaluation of the novel in vitro systems for hepatic drug clearance and assessment of their predictive utility 2012 ·Toxicology in Vitro ·J. Brian Houston, K Rowland‐Yeo, Ugo Zanelli	8
13	Application of a Systems Approach to the Bottom-Up Assessment of Pharmacokinetics in Obese Patients 2011 ·Clinical Pharmacokinetics ·Cyrus Ghobadi, Trevor N. Johnson, Mohsen Aarabi, Lisa M. Almond, Aurel Constant Allabi, K Rowland‐Yeo, Masoud Jamei, Amin Rostami‐Hodjegan	73
14	Prediction of human intestinal metabolism of CYP3A substrates using the Advanced, Dissolution, Absorption and Metabolism (ADAM) Model 2010 ·Research Explorer (The University of Manchester) ·(unknown), Himanshu Mishra, (unknown), K Rowland‐Yeo, Amin Rostami‐Hodjegan	1
15	A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance 2010 ·Clinical Pharmacokinetics ·Trevor N. Johnson, Koen Boussery, K Rowland‐Yeo, Geoffrey T. Tucker, Amin Rostami‐Hodjegan	181
16	A Critical Evaluation of the Experimental Design of Studies of Mechanism Based Enzyme Inhibition, with Implications for In Vitro-In Vivo Extrapolation 2006 ·Current Drug Metabolism ·Farshid Ghanbari, K Rowland‐Yeo, J. C. Bloomer, S. E. Clarke, Chris Lennard, Geoffrey T. Tucker, Amin Rostami‐Hodjegan	95
17	Prediction of metabolic drug clearance in humans:*In vitro–in vivoextrapolationvsallometric scaling 2006 ·Xenobiotica* ·Mohammad Bagher Shiran, (unknown), Eleanor Howgate, K Rowland‐Yeo, Geoffrey T. Tucker, Amin Rostami‐Hodjegan	65
18	Prediction ofin vivodrug clearance fromin vitrodata. II: Potential inter-ethnic differences 2006 ·Xenobiotica ·Shinichi Inoue, Eleanor Howgate, K Rowland‐Yeo, Tsutomu Shimada, Hiroshi Yamazaki, Geoffrey T. Tucker, Amin Rostami‐Hodjegan	69
19	The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy) 2006 ·Journal of Psychopharmacology ·(unknown), (unknown), Jiansong Yang, Judith Hargreaves, K Rowland‐Yeo, M. S. Lennard, Geoffrey T. Tucker, Amin Rostami‐Hodjegan	17
20	Protein binding of aspirin and salicylate measured by in vivo ultrafiltration* 1998 ·Clinical Pharmacology & Therapeutics ·Parviz Ghahramani, K Rowland‐Yeo, W W Yeo, Peter Jackson, Lawrence E. Ramsay	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact